UK regulators no longer exempt from paying successful parties' costs

The UK Supreme Court has ruled that regulators such as the Competition and Markets Authority (CMA) should be required to pay the costs of a party successfully appealing against one of their infringement decisions.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Antitrust regulators to increase scrutiny of biosimilar deals

4 February 2020 US competition regulators will increase scrutiny of biologic and biosimilar-related patent settlements, as they look to crack down on antitrust violations.

Americas

US regulators sue ‘pharma bro’ Shkreli over drug monopoly

28 January 2020 The US Federal Trade Commission and New York’s attorney general have sued incarcerated ‘pharma bro’ Martin Shkreli for allegedly monopolising the market for life-saving drug Daraprim.

Big Pharma

Competition watchdog fines big pharma duo £70m

22 July 2022 The pair are rapped for overcharging the NHS | Unfair prices for an epilepsy drug lasted four years | Costs leapt from £2m to £50m in one year after the companies' “illegal exploitation” of market position.

More on this story

Americas

Antitrust regulators to increase scrutiny of biosimilar deals

4 February 2020 US competition regulators will increase scrutiny of biologic and biosimilar-related patent settlements, as they look to crack down on antitrust violations.

Americas

US regulators sue ‘pharma bro’ Shkreli over drug monopoly

Big Pharma

Competition watchdog fines big pharma duo £70m

More on this story

Americas

Antitrust regulators to increase scrutiny of biosimilar deals

4 February 2020 US competition regulators will increase scrutiny of biologic and biosimilar-related patent settlements, as they look to crack down on antitrust violations.

Americas

US regulators sue ‘pharma bro’ Shkreli over drug monopoly

Big Pharma

Competition watchdog fines big pharma duo £70m